Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Pedersen, Sidsel Arnspang ; Johannesdottir Schmidt, Sigrun Alba ; Hölmich, Lisbet Rosenkrantz ; Friis, Søren ; Pottegård, Anton ; Gaist, David. / Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors : A nationwide case-control study. I: Journal of the American Academy of Dermatology. 2019 ; Bind 80, Nr. 2. s. 460-465.

Bibtex

@article{e376b9eefd2a422fa97c916a98b8da9e,
title = "Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study",
abstract = "BACKGROUND: Hydrochlorothiazide use has been associated with markedly increased risk of squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk of Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST).OBJECTIVE: To examine the association between hydrochlorothiazide use and the risk of MCC and MAST.METHODS: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated odds ratios (ORs) associated with cumulative use of hydrochlorothiazide.RESULTS: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95{\%} CI, 1.1-4.8) and 3.6 (95{\%} CI, 1.9-7.0), respectively, increasing to 3.3 (95{\%} CI 1.3-8.3) and 5.6 (95{\%} CI 2.4-13.3) with highest use (≥100,000mg). We found no increase in risk of the tumors in analyses of drugs with similar indications as hydrochlorothiazide, except a tendency toward an increased risk of MCC associated with use of furosemide (OR 1.9, 95{\%} CI 0.9-4.0).LIMITATIONS: No data on sun exposure was available.CONCLUSIONS: Hydrochlorothiazide use is associated with an increased risk of MCC and MAST.",
author = "Pedersen, {Sidsel Arnspang} and {Johannesdottir Schmidt}, {Sigrun Alba} and H{\"o}lmich, {Lisbet Rosenkrantz} and S{\o}ren Friis and Anton Potteg{\aa}rd and David Gaist",
note = "Copyright {\circledC} 2018. Published by Elsevier Inc.",
year = "2019",
month = "2",
day = "15",
doi = "10.1016/j.jaad.2018.06.014",
language = "English",
volume = "80",
pages = "460--465",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby, Inc",
number = "2",

}

RIS

TY - JOUR

T1 - Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors

T2 - A nationwide case-control study

AU - Pedersen, Sidsel Arnspang

AU - Johannesdottir Schmidt, Sigrun Alba

AU - Hölmich, Lisbet Rosenkrantz

AU - Friis, Søren

AU - Pottegård, Anton

AU - Gaist, David

N1 - Copyright © 2018. Published by Elsevier Inc.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - BACKGROUND: Hydrochlorothiazide use has been associated with markedly increased risk of squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk of Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST).OBJECTIVE: To examine the association between hydrochlorothiazide use and the risk of MCC and MAST.METHODS: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated odds ratios (ORs) associated with cumulative use of hydrochlorothiazide.RESULTS: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI, 1.1-4.8) and 3.6 (95% CI, 1.9-7.0), respectively, increasing to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3) with highest use (≥100,000mg). We found no increase in risk of the tumors in analyses of drugs with similar indications as hydrochlorothiazide, except a tendency toward an increased risk of MCC associated with use of furosemide (OR 1.9, 95% CI 0.9-4.0).LIMITATIONS: No data on sun exposure was available.CONCLUSIONS: Hydrochlorothiazide use is associated with an increased risk of MCC and MAST.

AB - BACKGROUND: Hydrochlorothiazide use has been associated with markedly increased risk of squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk of Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST).OBJECTIVE: To examine the association between hydrochlorothiazide use and the risk of MCC and MAST.METHODS: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated odds ratios (ORs) associated with cumulative use of hydrochlorothiazide.RESULTS: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI, 1.1-4.8) and 3.6 (95% CI, 1.9-7.0), respectively, increasing to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3) with highest use (≥100,000mg). We found no increase in risk of the tumors in analyses of drugs with similar indications as hydrochlorothiazide, except a tendency toward an increased risk of MCC associated with use of furosemide (OR 1.9, 95% CI 0.9-4.0).LIMITATIONS: No data on sun exposure was available.CONCLUSIONS: Hydrochlorothiazide use is associated with an increased risk of MCC and MAST.

U2 - 10.1016/j.jaad.2018.06.014

DO - 10.1016/j.jaad.2018.06.014

M3 - Journal article

VL - 80

SP - 460

EP - 465

JO - American Academy of Dermatology. Journal

JF - American Academy of Dermatology. Journal

SN - 0190-9622

IS - 2

ER -

ID: 55578625